-
Disposable Cardiac Pulsed Electric Field Ablation Catheter Approved for Marketing
2024-03-11
Recently, the innovative product Disposable Cardiac Pulsed Electric Field Ablation Catheter of Hangzhou Deno Electrophysiology Medical Technology Inc. was approved by China NMPA.
-
CT Image-aided Detection Software for Intracranial Aneurysms Approved for Marketing
2024-03-01
Recently, the innovative product CT Image-aided Detection Software for Intracranial Aneurysms of Hangzhou Deepwise was approved by China NMPA.
-
Reagents for Detection of Influenza A Viruses Approved by China NMPA
2024-02-01
So far, China NMPA has approved a total of 66 reagents for detection of influenza A viruses, including 23 antigen detection products, 5 antibody detection products, and 38 nucleic acid detection products.
-
Innovative TCM Qinwei Granules Approved for Marketing by China NMPA
2024-03-15
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Qinwei Granules of Chengdu Huaxi Natural Medicine Co Ltd was approved for marketing by the National Medical Products Administration.
-
Tunlametinib Capsules approved with conditions for marketing by China NMPA
2024-03-15
Recently, the Category 1 innovative drug Tunlametinib Capsules (Chinese trade name: 科露平) of Shanghai KeChow Pharmaceuticals Co. Ltd was approved with conditions for marketing by the National Medical Products Administration with priority review and approval, which is applicable to patients with advanced melanoma containing anti-PD-1/PD-L1 treatment failure of the NRAS mutation.
-
Rules for Labels of Prepared Slices of Chinese Crude Drugs Issued by China NMPA
2023-07-14
The NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024.
